Analysis Ranks Cost Effectiveness of First-Line Therapy Options for Advanced RCC
Renal & Urology News,
A cost-effectiveness study found that pembrolizumab plus axitinib was the most effective first-line strategy for patients with…
A cost-effectiveness study found that pembrolizumab plus axitinib was the most effective first-line strategy for patients with…
A cost-effectiveness study found that pembrolizumab plus axitinib was the most effective first-line strategy for patients with…